TOP NEWS: AstraZeneca says Evusheld shows promise on Covid variants

(Alliance News) - AstraZeneca PLC on Thursday said that new analyses from a phase 3 treatment ...

Alliance News 20 October, 2022 | 8:06AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - AstraZeneca PLC on Thursday said that new analyses from a phase 3 treatment trial show the potential of its Covid drug Evusheld to reduce severity and mortality.

New Tackle phase 3 data will highlight the activity of Evusheld against circulating Covid variants. Further, the Cambridge-based pharmaceutical company will present new data on its Covid vaccine Vaxzevria and its respiratory syncytial virus treatment Beyfortus.

In September, Beyfortus received recommendation for EU approval from the EU's European Medicine's Authority's Committee for Medicinal Products for Human Use. The drug was developed in cooperation with French partner Sanofi SA.

RSV is a common contagious virus affecting the lungs and breathing passages with no vaccines currently available for treatment. London-based pharmaceutical firm GSK PLC in June said it is close to developing the world's first RSV vaccine.

AstraZeneca will present the new data at the annual IDWeek conference in Washington DC that runs since Wednesday and until Sunday.

AstraZeneca shares were down 1.7% to 9,638.25 pence each in London on Thursday morning.

By Tom Budszus; tombudszus@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 11,352.00 GBX 0.75
Sanofi SA 87.70 EUR -1.29

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures